Denali Net Income From Continuing Ops from 2010 to 2026
| DNLI Stock | USD 19.18 0.51 2.59% |
Net Loss | First Reported 2015-12-31 | Previous Quarter -124.1 M | Current Value -126.9 M | Quarterly Volatility 79.3 M |
Check Denali Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Denali Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.1 M, Interest Expense of 8.9 M or Selling General Administrative of 127.3 M, as well as many indicators such as Price To Sales Ratio of 9.74, Dividend Yield of 0.0 or PTB Ratio of 2.17. Denali financial statements analysis is a perfect complement when working with Denali Therapeutics Valuation or Volatility modules.
Denali | Net Income From Continuing Ops | Build AI portfolio with Denali Stock |
The Net Income From Continuing Ops trend for Denali Therapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Denali Therapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Denali Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Denali Therapeutics over the last few years. It is Denali Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Denali Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Denali Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (137,786,919) | |
| Geometric Mean | 74,092,094 | |
| Coefficient Of Variation | (114.79) | |
| Mean Deviation | 135,553,424 | |
| Median | (86,652,000) | |
| Standard Deviation | 158,164,131 | |
| Sample Variance | 25015.9T | |
| Range | 495.6M | |
| R-Value | (0.79) | |
| Mean Square Error | 9928.4T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (24,819,324) | |
| Total Sum of Squares | 400254.3T |
Denali Net Income From Continuing Ops History
About Denali Therapeutics Financial Statements
Investors use fundamental indicators, such as Denali Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Denali Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Loss | -380.5 M | -361.5 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Denali Therapeutics Correlation against competitors. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is there potential for Biotechnology market expansion? Will Denali introduce new products? Factors like these will boost the valuation of Denali Therapeutics. Projected growth potential of Denali fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Denali Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Denali Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Denali Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.